

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A1	(11) International Publication Number:	WO 99/43801
C12N 15/12, C07K 14/71, A61K 38/17, 39/00, G01N 33/50, 33/68, C12Q 1/68, C07K 16/28		(43) International Publication Date:	2 September 1999 (02.09.99)
(21) International Application Number:	PCT/GB99/00583		University of Nottingham, City Hospital, Hucknall Road, Nottingham NG5 1PB (GB).
(22) International Filing Date:	26 February 1999 (26.02.99)		(74) Agents: O'BRIEN, Caroline, J. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).
(30) Priority Data:	9804121.3	26 February 1998 (26.02.98)	GB
(71) Applicant (<i>for all designated States except US</i>):	CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED [GB/GB]; Cambridge House, 6-10 Cambridge Terrace, Regent's Park, London NW1 4JL (GB).	(81) Designated States:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(72) Inventors; and		Published	
(75) Inventors/Applicants (<i>for US only</i>):	DURRANT, Linda, Gillian [GB/GB]; CRC Technology Limited, Dept. of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham NG5 1PB (GB). SPENDLOVE, Ian [GB/GB]; CRC Technology Limited, Dept. of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham NG5 1PB (GB). HEWETT, Peter, William [GB/GB]; CRC Technology Limited, Dept. of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham NG5 1PB (GB). RAMAGE, Judith, Margaret [GB/GB]; CRC Technology Limited, Dept. of Clinical Oncology,	With international search report. <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: ANTI-ANGIOGENIC VACCINES: SUBSTANCES AND METHODS RELATING THERETO

(57) Abstract

Short amino acid sequences which present epitopes of Tek protein can be used as cancer vaccines to direct an immune cell response to endothelial cells. The peptides and polypeptides bind to MHC molecules, and the presentation of Tek epitopes can stimulate helper and/or cytotoxic T cell responses. Nucleic acids encoding the peptides, antibodies directed against the peptides, and pharmaceutical compositions comprising the peptides are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

ANTI-ANGIOGENIC VACCINES: SUBSTANCES AND METHODS RELATING THERETO

Field of the invention

5 The present invention concerns materials and methods relating to anti-angiogenic vaccines.

Background to the invention

10 Solid tumours are dependent on the development of an adequate blood supply for growth and spread of metastasis. This is achieved by the growth of new blood vessels through the process of angiogenesis and parasitisation of pre-existing host vessels.

15 Several receptor tyrosine kinases (RTK) have been identified which are associated with endothelial cell proliferation and differentiation. These comprise the vascular endothelial growth factor (VEGF) family (Class III) RTKs, Flt-1, Flt-4, and KDR; and the Tie (Tie-1) (Partanen, J., et al 1992 Mol. Cell. Biol., 12 p1698) and Tek (also designated Tie-2) (Dumont, D.J. et al., 1992 Oncogene, 8 p147) RTKs. As both Tie and Tek have unique multiple extracellular domains consisting of immunoglobulin-like loops, epidermal growth factor-like repeats, and fibronectin type III repeats they are thought to represent a new family (Class VIII) of RTKs (Plate, K.H. et al., Brain Pathology 1994 4 p207-218). The Tek gene encodes a 140 kDa polypeptide and has been cloned from embryonic murine heart, murine brain capillaries and human placenta cDNA libraries (Dumont, D.J. et al., 1992 supra., Schnurch, H. and Risau, W. 1993 Development, 119 p957; Ziegler, S.F. et al., 1993 Oncogene 8 p663).

30

35 Accumulating evidence indicates that VEGF is the central

- mediator of developmental, hypoxia-mediated and tumour induced angiogenesis (Plate, K.H. et al., Brain Pathology 1994, 4 p207-218). VEGF, secreted by tumours, binds to endothelial cells which express VEGF RTKs FLT-1 and KDR.
- 5 FLT-1 is expressed by non endothelial cells including monocytes (Hewett, P., Biochem. Biophys. Res Comm. 1996, 221 p697-702) making it an inappropriate target for vaccines.
- 10 Although the exact role that Tie and Tek play in angiogenesis is still unclear, Tek has recently been observed in the endothelium of murine breast tumours (Millauer, B. et al., 1996 Cancer Res. 56 p1615) and it appears that Tek plays a pivotal role in the
- 15 differentiation, proliferation and survival of embryonic endothelium, as homozygous dominant-negative Tek mutants are not viable. A 1.2kb region of the murine Tek flanking sequence has been shown to act as an endothelial lineage-specific promoter during embryonic development in
- 20 transgenic mice (Schlaeger, T.M. et al., 1995 Development, 121 p1089). Tek is also known to be readily upregulated on HUVEC cells exposed to tumour conditioned medium (Hewett, P.W. et al., Br. J. Cancer 1996 73 p53-53). However this is no evidence that T cells recognise
- 25 receptor kinases overexpressed on endothelial cells.
- VEGF-receptors and PDGF receptors of subclass III of receptor kinases show structural homology. In relation to vaccine design, immune responses need to be directed to sequences unique to the VEGF receptors.
- 30
- Endothelial cells are in principal potential targets for T cell attack as they express class I MHC and can be induced to express class II MHC (Dhibjalbut S.S. et al., Journal of Immunology 1993, 151 p6248-6258). The
- 35

cytotoxicity of T cells for cerebral endothelial cells has been implicated in the breakdown of the blood brain barrier and development of inflammatory lesions in the central nervous system (Tsukada, N. et al., Autoimmunity 5 1994, 17 p225-232).

Summary of the invention

The present inventors have discovered that Tek has MHC binding epitopes which can bind to MHC to stimulate 10 helper and/or cytotoxic T cell responses in vitro.

The results described herein suggest that short amino acid sequences presenting epitopes of Tek can be used as cancer vaccines to direct an immune cell response to the 15 endothelia as evidenced by helper T cell responses including cytokine release and recruitment of non-specific effector cells such as natural killer cells or tumouricidal macrophages, stimulation of cytotoxic T cell responses or antibody responses.

20 Thus the present invention generally concerns agents based upon one or more of these epitopes which are in Tek for use as eg vaccines to target the endothelial cells lining the blood vessels of a tumour; methods for preparation of the agents; methods for preparation of 25 vaccines comprising as an essential constituent such agents; vaccines comprising such agents.

Provided by the present invention are peptides and 30 polypeptides which do not occur naturally and which consist essentially of one or more amino acid sequences that represent one or more epitopes of the Tek protein. The peptides or polypeptides, which comprise less than the full length polypeptide sequence of native Tek, can 35 bind to MHC to stimulate a helper and/or cytotoxic T cell

immune response.

By the terms "consists essentially of", it is intended to mean that peptides or polypeptides of the present invention consist largely of one or more sequences which represent epitopes of Tek protein, with little in the way of other sequences of the native Tek protein.

By the terms "represent one or more epitopes", it is intended to mean that the sequences are identical to, or differ only in immaterial variants of the sequence of a native Tek epitope, such that it retains the function of a Tek epitope.

Thus agents for use as eg vaccines may comprise such peptides/polypeptides or DNA constructs in the form of plasmids or vectors carrying nucleic acid encoding such peptides/polypeptides. DNA constructs may have appropriate regulatory sequences to control expression of the peptide/polypeptide. Vaccine vectors are well known in the art.

A polypeptide/peptide as provided may comprise less than the full-length Tek polypeptide sequence. It may have one or more sequences of at least 5 to 7 amino acids long, often at least about 7 to 9 amino acids long, typically at least about 9 to 13 amino acids long in common with the amino acid sequence of native Tek.

Polypeptide/peptide as provided may comprise less than 50%, often less than 40 or 30%, typically less than 20%, most preferably less than 5% of the amino acid sequence of native Tek. The polypeptide/peptide may comprise 30 or less, 25 or less, typically 20 or less, preferably 15 or less, most preferably 10 or less amino acids of native

Tek protein.

Polypeptide/peptide as provided may comprise amino acid sequence presenting a single epitope of the Tek protein.

5 Alternatively the polypeptide/peptide may comprise amino acid sequence presenting two or several epitopes of the Tek protein. The amino acid sequence may be such that the epitopes are contiguous or substantially contiguous. The amino acid sequence may be such that neighbouring 10 epitopes are substantially devoid of the amino acid sequence that occurs between them in the native Tek protein. Thus epitopes may be coupled by employment of suitable coupling partners. Both peptidyl and non-peptidyl coupling partners are well-known in the art.

15 Polypeptide/peptide as provided may be a fragment of native Tek protein, or recombinantly synthesised (ie to express nucleic acid coding for the polypeptide/peptide by use of the nucleic acid in an expression system) or 20 chemically synthesised. Polypeptides/peptides as provided may be generated wholly or partly by chemical synthesis. Thus they can be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods, general 25 descriptions of which are broadly available (see, for example, in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois (1984), in M. Bodanzsky and A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York (1984); and Applied Biosystems 430A 30 Users Manual, ABI Inc., Foster City, California), or they may be prepared in solution, by the liquid phase method or by any combination of solid-phase, liquid phase and solution chemistry, e.g. by first completing the 35 respective peptide portion and then, if desired and

appropriate, after removal of any protecting groups being present, by introduction of the residue X by reaction of the respective carbonic or sulfonic acid or a reactive derivative thereof.

5

The polypeptide/peptide may have the ability to bind to an MHC class I molecule and/or an MHC class II molecule. The polypeptide/peptide may be able to stimulate T cell proliferation. The polypeptide/peptide may have an amino acid sequence that appears within the amino acid sequence regions TEK1 (amino acids 55 to 90) TEK2 (amino acids 163 to 176) TEK3 (amino acids 345 to 362) TEK4 (amino acids 427 to 442) and TEK5 (amino acids 530 to 542) of the Tek polypeptide (see Fig.1). In particular, the polypeptide/peptide may comprise one of more of the epitope sequences Z1, Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9, Z11 and Z12 identified in Tables 1 and 4 or variant forms thereof which have substantially the same functional attributes. In particular the polypeptide/peptide may comprise the epitope sequence Z1 or Z32 identified in Tables 1 and 4 or variant forms thereof which have substantially the same functional attributes.

A variant form of an epitope sequence named above means a sequence modified by varying the sequence of amino acids eg by manipulation of encoding nucleic acid. The variation may involve insertion, addition, deletion or substitution of one or more amino acids, to provide an epitope sequence having substantially the same functional attributes of the epitope sequence from which the variant is derived.

Thus the amino acid sequence for Z1 is disclosed herein. It is also disclosed that Z1 binds HLA-A2 with a stabilisation ratio of 2.3 and is able to stimulate T-

cell proliferation. The amino acid sequence of Z1 may be slightly varied whilst retaining ability to bind HLA-A2 and stimulate T-cell proliferation.

5 Thus conservative variations may be made ie the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or
10 glutamine for asparagine.

Thus preferred such variants retain the function of the peptides from which they are derived. Such properties are mentioned above and identified herein. There may
15 also be immunological cross-reactivity with an antibody reactive to a peptide of Tek regions TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4; sharing an epitope with a peptide of Tek regions TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4 (as determined
20 for example by immunological cross-reactivity between the two peptides).

A variant form of a peptide from Tek regions TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4 may
25 comprise an amino acid sequence which shares greater than about 30% sequence identity with the sequence shown, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80% or greater than about 90%. The sequence may share greater than about 60% similarity, greater than about 70% similarity, greater than about 80% similarity or greater than about 90% similarity with an amino acid sequence from Tek regions TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4. Particular amino acid
30 sequence variants may differ from those from Tek regions
35

TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4 by insertion, addition, substitution or deletion of 1 amino acid, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 amino acids.

5

The polypeptide/peptide may comprise two or more epitope sequences from Tek regions TEK1 to 5, (see Fig.1) or as identified in Tables 1 and 4 or two or more variants of epitope sequences from Tek regions TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4. Thus the polypeptide/peptide may comprise the Z32 epitope sequence of Table 4.

10 The peptide may have an amino acid sequence shown in Table 1 or Table 4.

15 Polypeptides/peptides as provided may be in isolated and/or purified form, free or substantially free of material with which it is naturally associated.

20

A polypeptide/peptide as provided may be isolated and/or purified (e.g. using an antibody) for instance after production by expression from encoding nucleic acid. They may also be generated wholly or partly by chemical synthesis. They may be used in the formulation of a composition, which may include at least one additional component, for example a pharmaceutical composition including a pharmaceutically acceptable excipient, vehicle or carrier. A composition including a polypeptide/peptide as provided may be used in prophylactic and/or therapeutic treatment as discussed below.

25 30 35 A polypeptide/peptide as provided may be used as an immunogen or otherwise in obtaining specific antibodies.

Antibodies are useful in eg purification and other manipulative techniques.

The production of monoclonal antibodies is well established in the art. Monoclonal antibodies can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB-A-2188638 or EP-A-239400. A hybridoma producing a monoclonal antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.

The provision of the novel polypeptides/peptides enables for the first time the production of antibodies able to bind specifically to them. Accordingly, a further aspect of the present invention provides an antibody able to bind specifically to a peptide Tek regions TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4 or variant peptide thereof as discussed. Such an antibody may be specific in the sense of being able to distinguish between the peptide it is able to bind and other peptides for which it has no or substantially no binding affinity (e.g. a binding affinity of about 1000x worse). Specific antibodies bind an epitope on the molecule which is either not present or is not accessible on other molecules. Antibodies according to the present invention may be specific for the wild-type polypeptide. Antibodies are also useful in purifying the peptides or polypeptides to which they bind, e.g. following

production by recombinant expression from encoding nucleic acid.

Preferred antibodies according to the invention are
5 isolated, in the sense of being free from contaminants such as antibodies able to bind other polypeptides and/or free of serum components. Monoclonal antibodies are preferred for some purposes, though polyclonal antibodies are within the scope of the present invention.

10 Antibodies may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be
15 used (Armitage et al, Nature, 357:80-82, 1992).
20 Isolation of antibodies and/or antibody-producing cells from an animal may be accompanied by a step of sacrificing the animal.

25 As an alternative or supplement to immunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which
30 display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047. The library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with any of the proteins (or fragments), or may be one constructed
35 using sequences obtained from an organism which has been

exposed to the antigen of interest.

Antibodies according to the present invention may be modified in a number of ways. Indeed the term "antibody" 5 should be construed as covering any binding substance having a binding domain with the required specificity. Thus the invention covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic molecules and molecules 10 whose shape mimics that of an antibody enabling it to bind an antigen or epitope.

Example antibody fragments, capable of binding an antigen or other binding partner are the Fab fragment consisting 15 of the VL, VH, Cl and CH1 domains; the Fd fragment consisting of the VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')² fragments, a bivalent 20 fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included.

Antibodies may be humanised if appropriate ie CDRs from a 25 non-human source grafted onto human framework regions, typically with the alteration of some of the framework amino acid residues.

A hybridoma producing a monoclonal antibody for the 30 peptides herein may be subject to genetic mutation or other changes. It will further be understood by those skilled in the art that a monoclonal antibody can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which 35 retain the specificity of the original antibody. Such

- techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB-A-2188638 or EP-A-0239400. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.
- Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or prokaryotic, containing nucleic acid encoding antibodies (including antibody fragments) and capable of their expression. The invention also provides methods of production of the antibodies including growing a cell capable of producing the antibody under conditions in which the antibody is produced, and preferably secreted.
- The reactivities of antibodies on a sample may be determined by any appropriate means. Tagging with individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule.
- One favoured mode is by covalent linkage of each antibody with an individual fluorochrome, phosphor or laser dye with spectrally isolated absorption or emission characteristics. Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red.

Suitable chromogenic dyes include diaminobenzidine.

Other reporters include macromolecular colloidal particles or particulate material such as latex beads
5 that are coloured, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded. These molecules may be enzymes which catalyse reactions that develop or change colours or cause changes
10 in electrical properties, for example. They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical
15 entities used in conjunction with biosensors.
Biotin/avidin or biotin/streptavidin and alkaline phosphatase detection systems may be employed.

The mode of determining binding is not a feature of the
20 present invention and those skilled in the art are able to choose a suitable mode according to their preference and general knowledge.

An antibody may be provided in a kit, which may include
25 instructions for use of the antibody, e.g. in determining the presence of a particular substance in a test sample. One or more other reagents may be included, such as labelling molecules, buffer solutions, elutants and so on. Reagents may be provided within containers which
30 protect them from the external environment, such as a sealed vial.

Figure 1 discloses areas (TEK1 to 5) of the Tek polypeptide potentially containing T cell epitopes and
35 Tables 1 and 4 provide amino acids for useful peptides

from the areas TEK1 to 5 the inventors have discovered as being of interest as effective agents of anti-cancer vaccines. Thus the present invention provides nucleic acid molecules which encode polypeptides/peptides as provided above. Nucleotide sequences for peptides of Tek regions TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4 or variants thereof may be readily produced applying common knowledge of the genetic code. Nucleic acid encoding a peptide which is an amino acid sequence variant of a peptide sequence of Tek regions TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4 are provided.

Generally nucleic acid according to the present invention is provided as an isolate, in isolated and/or purified form, or free or substantially free of material with which it is naturally associated, such as free or substantially free of nucleic acid coding for sequences flanking sequences of interest, except possibly one or more regulatory sequence(s) for expression. Nucleic acid may be wholly or partially synthetic and may include genomic DNA, cDNA or RNA. Where nucleic acid according to the invention includes RNA, reference to the sequence shown should be construed as reference to the RNA equivalent, with U substituted for T.

Nucleic acid sequences as provided and/or accompanying regulatory elements can be readily prepared by the skilled person using the information and references contained herein and techniques known in the art (for example, see Sambrook, Fritsch and Maniatis, "Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, and Ausubel et al, Short Protocols in Molecular Biology, John Wiley and Sons, 1992). These techniques include (i) the use of the

polymerase chain reaction (PCR) to amplify samples of such nucleic acid, e.g. from genomic sources, (ii) chemical synthesis, or (iii) preparing cDNA sequences. Modifications to the sequences can be made, e.g. using 5 site directed mutagenesis, to lead to the expression of modified peptide/polypeptide or to take account of codon preference in the host cells used to express the nucleic acid.

10 In order to obtain expression of nucleic acid sequences as provided, the sequences can be incorporated in a vector having control sequences operably linked to control its expression. The vectors may include other sequences such as promoters or enhancers to drive the 15 expression of the inserted nucleic acid, nucleic acid sequences so that polypeptide is produced as a fusion and/or nucleic acid encoding secretion signals so that the polypeptide/peptide produced in the host cell is secreted from the cell. Polypeptide/peptide can then be 20 obtained by transforming the vectors into host cells in which the vector is functional, culturing the host cells so that the polypeptide/peptide is produced and recovering (eg by use of an antibody) the polypeptide/peptide from the host cells or the 25 surrounding medium. Prokaryotic and eukaryotic cells are used for this purpose in the art, including strains of E. coli, yeast, and eukaryotic cells such as COS or CHO cells. The choice of host cell can be used to control the properties of the polypeptide/peptide expressed in those 30 cells, e.g. controlling where the polypeptide/peptide is deposited in the host cells or affecting properties such as its glycosylation.

35 PCR techniques for the amplification of nucleic acid are described in US Patent No. 4,683,195. In general, such

techniques require that sequence information from the ends of the target sequence is known to allow suitable forward and reverse oligonucleotide primers to be designed to be identical or similar to the polynucleotide sequence that is the target for the amplification. PCR comprises steps of denaturation of template nucleic acid (if double-stranded), annealing of primer to target, and polymerisation. The nucleic acid probed or used as template in the amplification reaction may be genomic DNA, cDNA or RNA. PCR can be used to amplify specific sequences from genomic DNA, specific RNA sequences and cDNA transcribed from mRNA, bacteriophage or plasmid sequences. The Tek nucleic acid sequences (see Figs.1 and 2 and Tables 1 and 4) herein readily allow the skilled person to design PCR primers to identify, isolate or prepare polypeptides/peptides of the invention.

References for the general use of PCR techniques include Mullis et al, Cold Spring Harbor Symp. Quant. Biol., 51:263, (1987), Ehrlich (ed), PCR technology, Stockton Press, NY, 1989, Ehrlich et al, Science, 252:1643-1650, (1991), "PCR protocols; A Guide to Methods and Applications", Eds. Innis et al, Academic Press, New York, (1990).

The nucleic acid sequences coding for polypeptides/peptides as provided are useful for identifying nucleic acid of interest (and which may be according to the present invention) in a test sample. The present invention provides a method of obtaining nucleic acid of interest, the method including hybridisation of a probe having sequence coding for a peptide of Tek regions TEK1 to 5 (see Fig.1) or as identified in Tables 1 and 4 or a complementary sequence, to target nucleic acid.

Hybridisation is generally followed by identification of successful hybridisation and isolation of nucleic acid which has hybridised to the probe, which may involve one or more steps of PCR.

5

Nucleic acid according to the present invention is obtainable using one or more oligonucleotide probes or primers designed to hybridise with nucleic acid sequence coding for a peptide of Tek regions TEK1 to 5 (see Fig.1) 10 or as identified in Tables 1 and 4. A primer may be used in conjunction with one or more oligonucleotides designed to hybridise to a sequence in a cloning vector within which target nucleic acid has been cloned, or in so-called "RACE" (rapid amplification of cDNA ends) in which 15 cDNA's in a library are ligated to an oligonucleotide linker and PCR is performed using a primer which hybridises with the template sequence of interest and a primer which hybridises to the oligonucleotide linker.

20

On the basis of amino acid sequence information, oligonucleotide probes or primers may be designed, taking into account the degeneracy of the genetic code, and, where appropriate, codon usage of the organism from the candidate nucleic acid is derived. An oligonucleotide 25 for use in nucleic acid amplification may have about 10 or fewer codons (e.g. 6, 7 or 8), i.e. be about 30 or fewer nucleotides in length (e.g. 18, 21 or 24). Generally specific primers are upwards of 14 nucleotides in length, but not more than 18-20. Those skilled in the 30 art are well versed in the design of primers for use processes such as PCR.

Nucleic acid according to the present invention may be provided as part of a kit, e.g. in a suitable container 35 such as a vial in which the contents are protected from

the external environment.

A convenient way of producing a polypeptide/peptide according to the present invention is to express nucleic acid encoding it in an expression system. The use of expression systems has reached an advanced degree of sophistication today.

Accordingly, the present invention also encompasses a method of making a polypeptide/peptide (as disclosed), the method including expression from nucleic acid encoding the polypeptide/peptide (generally nucleic acid according to the invention). This may conveniently be achieved by growing in culture a host cell containing a vector carrying the nucleic acid, under appropriate conditions which cause or allow expression of the polypeptide/peptide. Expression may be in in vitro systems, such as reticulocyte lysate.

Systems for cloning and expression of a polypeptide/peptide in a variety of different host cells are well known. Suitable host cells include bacteria, eukaryotic cells such as mammalian and yeast, and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, COS cells and many others. A common, preferred bacterial host is E. coli.

Thus a further aspect of the present invention provides a vector comprising nucleic acid as provided.

Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation

sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. 'phage, or phagemid, as appropriate. Suitable virus vectors include herpesviruses, adenoviruses, poxviruses and retroviruses, as well as other such viruses commonly used in the art. For further details see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons, 1992.

A plasmid comprising nucleic acid as provided may be used as an immunogen (ie an anti-cancer vaccine) and injected i.m or i.d to stimulate direction a T cell response to the endothelial cells of a tumour.

A further aspect of the present invention provides a host cell containing nucleic acid as provided. The nucleic acid may be integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques. The nucleic acid may be on an extra-chromosomal vector within the cell.

A still further aspect provides a method which includes introducing nucleic acid as provided into a host cell. The introduction, which may (particularly for *in vitro* introduction) be generally referred to without limitation as "transformation", may employ any available technique.

- For eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. 5 vaccinia or, for insect cells, baculovirus. For bacterial cells, suitable techniques may include calcium chloride transformation, electroporation and transfection using bacteriophage. As an alternative, direct injection of the nucleic acid could be employed.
- Marker genes such as antibiotic resistance or sensitivity genes may be used in identifying clones containing nucleic acid of interest, as is well known in the art.
- The introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells (which may include cells actually transformed although more likely the cells will be descendants of the transformed cells) under conditions for expression of the gene, so that the encoded polypeptide/peptide is produced. If the polypeptide/peptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell into the culture medium. Following production by expression, the expression product may be isolated and/or purified from the host cell and/or culture medium, as the case may be, and subsequently used as desired, e.g. in the formulation of a composition which may include one or more additional components, such as a pharmaceutical composition which includes one or more pharmaceutically acceptable excipients, vehicles or carriers (e.g. see below). A host cell containing nucleic acid according to the present invention, e.g. as a result of introduction of 35 nucleic acid into the cell or into an ancestor of the

cell and/or genetic alteration of the sequence endogenous to the cell or ancestor (which introduction or alteration may take place in vivo or ex vivo), may be comprised (e.g. in the soma) within an organism which is an animal, particularly a mammal, which may be human or non-human, such as rabbit, guinea pig, rat, mouse or other rodent, cat, dog, pig, sheep, goat, cattle or horse, or which is a bird, such as a chicken. Genetically modified or transgenic animals or birds comprising such a cell are also provided as further aspects of the present invention.

Thus host cells may be used as a nucleic acid factory to replicate the nucleic acid of interest in order to generate large amounts of it. Multiple copies of nucleic acid of interest may be made within a cell when coupled to an amplifiable gene such as DHFR. Host cells transformed with nucleic acid of interest, or which are descended from host cells into which nucleic acid was introduced, may be cultured under suitable conditions, e.g. in a fermenter, taken from the culture and subjected to processing to purify the nucleic acid.

The skilled person can use the techniques described herein and others well known in the art to produce large amounts of the polypeptides/peptides of the invention for use as pharmaceuticals, in the developments of drugs and for further study into their properties and role in vivo.

As mentioned above the polypeptides/peptides provided and also nucleic acid constructs (eg viral vaccine) can be formulated in pharmaceutical compositions. These compositions may in addition comprise a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art.

Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral,
5 intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes. The formulation may be liquid and ordinarily a physiologic salt solution containing non-phosphate buffer at pH 6.8-7.6, or may be lyophilized powder.

10

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

15

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers,
25 buffers, antioxidants and/or other additives may be included, as required.

30 Administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount"
35 (as the case may be, although prophylaxis may be

considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being
5 treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of
10 delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed),
15 1980.

15 A polypeptide/peptide as taught may be prepared for administration by mixing at the desired degree of purity with adjuvants or physiologically acceptable carriers, i.e. carriers which are non toxic to recipients at the
20 dosages and concentrations employed. Adjuvants and carriers are substances that in themselves share no immune epitopes with the target antigen, but which stimulate the immune response to the target antigen. Ordinarily, this will entail combining active ingredient
25 with buffers, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose or dextrans, cheating agents such as EDTA, and other excipients. Freunds adjuvant (a mineral oil emulsion) commonly has been used
30 for this purpose, as have a variety of toxic microbial substances such as mycobacterial extracts and cytokines such as tumour necrosis factor and interferon gamma. Other adjuvants for vaccination are disclosed in EP-A-0745388, WO97/01330 and EP-A-0781559. Carriers can also
35 act as adjuvants, but are generally distinguished from

adjuvants in that carriers comprise water insoluble macromolecular particulate structures which aggregate the antigen, typical carriers include aluminum hydroxide, latex particles, bentonite and liposomes.

5

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

10

Administration may be via injection (intramuscular or subcutaneous) intravenous delivery, or delivery through catheter or other surgical tubing. Alternative routes include tablets and the like, commercially available nebulizers for liquid formulations, and inhalation of lyophilized or aerosolized receptors. Liquid formulations may be utilized after reconstitution from powder formulations.

20

The polypeptides/peptides taught may also be administered via microspheres, liposomes, other microparticulate delivery systems or sustained release formulations placed in certain tissues including blood. Suitable examples of sustained release carriers include semipermeable polymer matrices in the form of shaped articles, e.g.

25

suppositories, or microcapsules. Implantable or microcapsular sustained release matrices include polylactides (US Patent No:3,773,919, EP-A-0058481) copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al, Biopolymers 22(1): 547-556, 1985), poly(2-hydroxyethyl-methacrylate) or ethylene vinyl acetate (Langer et al, J. Biomed. Mater. Res. 15:167-277, 1981, and Langer, Chem. Tech. 12:98-105, 1982). Liposomes containing the polypeptides are prepared by well-known methods: DE 3,218,121A; Epstein et al, PNAS USA, 82:3688-3692, 1985; Hwang et al, PNAS USA, 77:4030-4034,

1980; EP-A-0052522; E-A-0036676; EP-A-0088046; EP-A-0143949; EP-A-0142541; JP-A-83-11808; US Patent Nos 4,485,045 and 4,544,545. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected proportion being adjusted for the optimal rate of the polypeptide leakage.

The vaccination dose will be dependent upon the properties of the vaccine employed, e.g. its binding activity and in vivo plasma half-life, the concentration of the polypeptide in the formulation, the administration route, the site and rate of dosage, the clinical tolerance of the patient involved, the pathological condition afflicting the patient and the like, as is well within the skill of the physician. For example, doses of 300 µg of polypeptide per patient per administration are preferred, although dosages may range from about 10 µg-1 mg per dose. Different dosages are utilized during a series of sequential inoculations; the practitioner may administer an initial inoculation and then boost with relatively smaller doses of vaccine.

The vaccine compositions of the invention can be administered in a variety of ways and to different classes of recipients.

At least three separate inoculations with the polypeptides/peptides may be administered, with a second inoculation being administered more than two, preferably three to eight, and more preferably approximately four weeks following the first inoculation. A third inoculation may be administered several months later than the second "boost" inoculation, preferably at least more than five months following the first inoculation, more

preferably six months to two years following the first inoculation, and even more preferably eight months to one year following the first inoculation. Periodic inoculations beyond the third are also desirable to
5 enhance the patient's "immune memory". See Anderson et al, J Infectious Diseases 160 (6):960-969, Dec.1989 and the references therein. Generally, infrequent immunizations with polypeptides spaced at relatively long intervals is more preferred than frequent immunizations
10 in eliciting maximum antibody responses, and in eliciting a protective effect.

Alternatively, targeting therapies may be used to deliver the active agent more specifically to certain types of
15 cell, by the use of targeting systems such as antibody or cell specific ligands. Targeting may be desirable for a variety of reasons; for example if the agent is unacceptably toxic, or if it would otherwise require too high a dosage, or if it would not otherwise be able to
20 enter the target cells.

Instead of administering polypeptides/peptides directly, their production in target cells can be achieved by expression from an encoding gene introduced into the
25 cells, eg in a viral vector (a variant of the VDEPT technique - see below). The vector could be targeted to the specific cells to be treated, or it could contain regulatory elements which are switched on more or less selectively by the target cells. Vectors such as viral
30 vaccine vectors have been used in the prior art. In particular, a number of viruses have been used poxviruses such as vaccinia virus. Alternatives are well known. A variety of vectors, both viral vectors and plasmid vectors are known in the art, see US Patent No. 5,252,479
35 and WO93/07282.

The agent may be administered in a precursor form, for conversion to the active form by an activating agent produced in, or targeted to, the cells to be treated. This type of approach is sometimes known as ADEPT or 5 VDEPT, the former involving targeting the activating agent to the cells by conjugation to a cell-specific antibody, while the latter involves producing the activating agent, e.g. an enzyme, in a vector by expression from encoding DNA in a viral vector (see for 10 example, EP-A-415731 and WO 90/07936).

Further vaccination may be achieved by simple injection of naked DNA in accordance with recent reports which show that injection of naked DNA encoding an immunogen either 15 directly into muscle cells or as DNA coated micogold particles via a gene gun into skin cells. In the latter case some beads are taken up by dendritic cells and transported to the draining lymph nodes. This procedure has resulted in prolonged humoral and cell mediated 20 immunity. It therefore offers all the advantages of live viral vaccines as protein is continuously produced within antigen presenting cells, but is safer as the DNA is engineered to contain only the genes for the immunogenic protein. DNA encoding the protein/polypeptide of 25 interest is cloned into a suitable expression vector such as the eukaryotic expression vector pCR3 (Invitrogen). Inclusion of signal sequences will be used to target the translated protein to class I or class II compartments. In relation to the treatment of tumours, vaccines which 30 direct an immune response to endothelia offer a number of advantages over vaccines targeting a response to epithelia.

Firstly since each capillary provides oxygen and 35 nutrients for thousands of tumour cells, even limited

damage to the tumour vasculature would result in large scale destruction of tumour cells. Secondly endothelial cells are directly accessible to the immune system and thirdly the problems of antigen heterogeneity, MHC loss and resistance to apoptosis which are associated with mutant epithelial cells are unlikely to occur where the immune response is directed to normal endothelial cells. Finally, tumour endothelial cells overexpress molecules including a range of tyrosine kinase receptors such as
5 Tek.
10

In order that the present invention is better understood there follows a description of the experimental work underlying the discovery. The description also provides
15 detailed information relating to the identification, provision and use of peptide epitopes which the inventors propose are valuable in the preparation of useful anti-tumour vaccines.

20 Reference is made to the accompanying figures which are described below.

Brief description of the drawings

Figure 1. Shows the sequence for Tek and identifies five
25 potential T cell epitopes in the immunoglobulin-like loops and around the EGF-like and fibronectin type III-like domains.

Figure 2. Shows Genbank sequence alignments which indicate restriction of the potential T cell epitopes to
30 Tek.

Figure 3. Shows the results of an experiment to measure the ability of the peptides identified to bind to HLA-A2
35 (measured by quantifying the surface expression of HLA-A2

molecules on T2 cell line by indirect immunofluorescence with W6/32 monoclonal antibody and flow cytometric analysis; peptides were B6 hepatitis surface antigen peptide (FLPSDFFPSV), D1 MAGE HLA-A1 peptide (EVDPIGHLY) and Tek peptides Z1 and Z12).

Figure 4. Shows the results of an experiment to measure T cell proliferation responses of volunteer 1.

Figure 5. Hydropathicity Profile for Tek.

Detailed description of the drawings and exemplification of the invention

15 EXPERIMENTAL

METHODS

Potential T cell epitopes have been identified within overexpressed tyrosine kinases by motif analysis and/or 20 overlapping peptide analysis. These epitopes have been confirmed *in vitro* by binding to human MHC and stimulation of helper and cytotoxic T cell responses.

Motif Analysis

25 Different sets of peptides are displayed by individual class I isoforms with each MHC class I molecule having its individual peptide specificity, or motif, usually characterised by a defined number of amino acids and two anchor residues. The latter represent interaction sites 30 with the MHC binding groove, as revealed by crystallography. One anchor is at the C-terminus of peptides and is either hydrophobic or positively charged: a second anchor is at position 2, 3, or 5 (Germain R.N. The Immunologist 1995, 3 p185-190).

MHC class II molecules also display allele-specific peptide ligand motifs. Their determination has been more difficult than for class I because class II ligands have their N- and C- termini protruding out of the MHC groove, which tightly holds a nonamer stretch in the middle of 12 to 25-mer peptides. Analysis of over 9,000 peptides eluted from MHC molecules has identified over 200 motifs binding to a wide range of MHC phenotypes (Brusic, V. et al., Nucl. Acids Res. 1994, 22 p3663-3665). These motifs can be used to analyse proteins to identify potential T cell epitopes. Although having the correct anchor residue (motif) is necessary for MHC binding it is by no means sufficient, as non-anchor residues can exert important effects on both MHC peptide binding and T cell stimulation.

The present inventors have analysed the structure of Tek in order to identify areas that appear unique to the receptors and which display a potential for T-cell epitope generation. The inventors have identified five potential epitopes in the immunoglobulin-like loops of Tek and around the EGF-like and fibronectin type III-like domains (Fig.1). These potential epitopes have been rechecked against the Genbank database. It appears that the epitopes are restricted to Tek (Fig.2). Peptides based on these results have been synthesised and tested for MHC binding.

Table 1 identifies potential T cell epitopes within Tek.

Table 1

Amino Acid Sequences of the Peptides Identified as Potential T Cell Epitopes Within Tek. The Tek region is as specified in Figure 1.

5

10

15

20

Peptide	Amino acid sequence	TEK region
Z9	GMVEKPFNI	TEK4
Z5	RMTPKIVDL	TEK3
Z1	LMNQHQDPL	TEK1
Z3	TIGRDFEAL	TEK1
Z2	NQHQDPLEV	TEK1
Z4	PRHEVPDIL	TEK2
Z6	KIVDLPDHI	TEK3
Z8	GIPRMTPKIV	TEK3
Z11	NLHPREQYV	TEK aa 606-614
Z12	ILINSLPLV	TEK aa 27-36
Z7	IVDLPDHIEV	TEK3 aa 353-362

Peptides of the table were synthesised and tested for binding to HLA-A2 molecules on the T2 cell line.

Binding of Peptides to HLA-A2

25

30

The ability of peptides to bind to HLA-A2 was measured by quantifying the surface expression of HLA-A2 molecules on T2 cell line. These cells originate from a TAP deficient cell line which can not process peptides. MHC class I molecules are unstable in the absence of peptide and therefore this cell line only expresses 20-40% of the MHC it produces. Incubation of T2 cells with MHC binding peptides can stabilise MHC and enhance surface expression (Celis, E. et al., Proc. Natl. Acad. Sci. USA 1994, 91

32

p2105-9).

T2 cells were harvested and washed once in serum free (S/F) RPMI. Cells were aliquoted into 96 U well plates at 2 x 10⁵/well in 100µl of S/F RPMI. Peptides (0.1-1000µg/ml) were added and left at 26°C in a 5% CO₂ incubator overnight. Expression of HLA molecules was measured by indirect immunofluorescence and results were analysed by flow cytometry. Unbound peptide was removed by washing in S/F RPMI. W6/32 (anti-HLA,A,B,C) antibody was added at 1/100 dilution in 100µl of S/F RPMI for 45 minutes on ice. Cells were washed once in S/F RPMI and then incubated on ice for 45 minutes with 100µl of rabbit anti mouse FITC added (1/1000 dilution in S/F RPMI). Cells were washed and fixed in 800µl of cellfix (1 in 10 dilution with water).

The results are summarised in Table 2 below.

20

25

30

35

Table 2

Stabilisation of HLA-A2 on the Surface of T2 Cells by Incubation with Peptides.

5

Peptide	HLA-A2 stabilisation ratio ^a
Z1	2.3
Z2	2.2
Z6	1.9
Z12	1.8
Z5	1.8
Z11	1.6
Z9	1.5
Z3	1.5
Z8	1.3
Z4	1.0

a) stabilisation ratio, Fluorescence in the presence of peptide/fluorescence without peptide.

20

Of the ten peptides only one (Z4) failed to bind to HLA-A2. Five of the peptides (Z1, Z2, Z6, Z12, Z5) showed strong binding as indicated by a stabilisation ratio >1.7. Three of the peptides (Z11, Z9, Z3) showed moderate binding as indicated by a stabilisation ratio of 1.5 to 1.7. One peptide (Z8) showed weak binding (stabilisation ratio of 1.3).

25

The two peptides (Z1 and Z12) which gave high stabilisation ratios were incubated with T2 cells at varying concentrations. The results for this experiment are shown in Fig.3. Z1 showed the highest affinity with 50% of maximum HLA stabilisation at 5 μ g/ml whereas

20 μ g/ml of Z12 were required.

T Cell Responses

- 5 Three of these TEK peptides (Z1, Z3, Z7) were investigated for stimulation of T cell proliferation. Blood samples were obtained from healthy volunteers. Peripheral blood mononuclear cells (PBMC) were obtained following centrifugation on Ficoll-Paque (Pharmacia Biotechnology Ltd., Milton Keynes, UK) at 220g for 30 minutes. Cells were cultured in RPMI (Sigma) with 5% human pre-screened male AB⁺ and 5mM HEPES (Sigma) as follows: 1x10⁶ mononuclear cells/ml or 1x10⁶ separated T cells/ml with 1x10⁵ adherent cells/ml, in 2ml volumes in a 10 24 well plate (Nunc (Gibco) Life Technologies, Paisley, UK) with the appropriate concentration of antigen. The following antigens were used, at previously determined 15 optimal concentrations: PPD (Statens Serum Institut, Copenhagen, Denmark) at 10mg/ml; KLH (Calbiochem, Nottingham, UK) at 50mg/ml and the Tek peptides at 20 20mg/ml. Two ml cultures were sampled at different time points, between days 4 to 10, by transferring three 100ml aliquots from each well into 96 well microtitre plates and pulsing with 0.5mCi ³H-thymidine/well for 6 hours. 25 Samples were harvested onto printed filter mats (Wallac, Milton Keynes, UK) by means of a cell harvester (Skatron, Oslo, Norway), and ³H-thymidine incorporation was measured using a b plate counter.
- 30 Enrichment of CD45RA+ cells: antigen presenting cells (APC) were obtained by adherence of PBMC in 175cm³ flasks for one hour at 37°C. CD45RA+ enriched T cells were negatively selected from the non-adherent cells using immunomagnetic depletion with sheep-anti-mouse IgG-coated 35 Dynabeads (Dynal) previously incubated with an anti-CD8

antibody (Dynal).

The peptides Z1, Z3, Z7 stimulated blastogenesis responses *in vitro* on naive lymphocytes of the appropriate haplotype. The results are presented in 5 Table 3 below.

Table 3

10 Proliferation Responses of Human T Cells to Tek peptides Z1, Z3, Z7 and Z32.

Volunteer	Day of peak response	Control	Z32 (cpm)	Z1	Z3	Z7	HLA-DR type
1	9	447	nd	3197	566	2314	1, 4
15	2	8	1957	8538			3;
3	7	12920	37685				3, 7
4	6	644	7785				2:11
5	6	1549	2638				3, 5
20	6	7	2548	4180			1, 13

A 20 amino acid peptide (Z32) from Tek region 1 which encompasses both the Z1 and Z3 sequences was also synthesised and screened for blastogenesis responses. The sequence for this peptide is shown in Table 4 below.

25 The inventors suspected that this peptide would stimulate proliferation in donors of HLA-DR1, 3, 4, 7, 8 haplotypes and possibly in most donors as it has a promiscuous pan DR binding motif (Chicz, R.M. et al., J. Exp. Med. 1993, 30 178 p27-47). The results are shown in Table 4 below.

Table 4

The Z32 Peptide and the Sequences Thereof which are Predicted to Bind to the Specified MHC Haplotypes.

5

20 All of the donors tested responded to the Z32 peptide. Typical proliferation responses from donor 1 to Tek peptides and the recall antigen PPD or the primary antigen KLH are shown in Fig.4.

25 The binding of Z32 peptide to HLA-A2, 3, 11, 24, B8 and
B27 may be investigated by CTL assays. CTL activity is
screened against a range of chromium labelled HLA-A
matched target cells. Initially CTLs are screened
against peptide pulsed lymphocytes to verify the
induction of CTLs. CTL activity is then verified against
30 cells transfected with mini gene or truncated gene
constructs to demonstrate target antigen processing and
presentation by MHC class I antigens. CTL activity is

screened against HUVEC induced to express high levels of Tek by tumour conditioned medium to verify that recognition by peptide induced CTLs of endogenously processed target antigens.

5

Immunisation with Tek specific peptides will induce antibodies which bind to tumour endothelial cells and promote coagulation and thrombosis. The sequence of Tek was analysed for hydrophilicity (Fig. 5). Antibodies are 10 more likely to bind to hydrophilic areas of antigens, in particular to regions which change from hydrophobic to hydrophilic. The Z32 peptide spans such a region.

15 Z32 peptide (or other peptides) can be used to immunise a suitable animal in accordance with standard procedures. Serum is screened for an antibody reaction with the Tek protein.

20 The identification of stimulating epitopes from angiogenic targets allows the design of vaccines for the effective generation of cytotoxic and helper T cells. The immunogen may be in the form of antigen, anti-idiotypic antibody or specific epitopes. The immunogen may be presented as either protein/polypeptide/peptide or 25 as DNA constructs design for the expression of suitable protein/polypeptide/peptide. Effective portions of the full-length KDR or Tek proteins will be advantageous in that the full-length sequences have homology to a range of other tyrosine kinases. The truncated forms will have 30 the epitopes identified as being associated with helper and cytotoxic T cell responses. The use of minigenes provides a rapid easy means of generating vaccines. Bicistronic constructs can be readily designed in which 35 for example both CTL and helper epitopes are carried on a single plasmid.

Where T cell epitopes expressed by endothelial receptors stimulate either helper and/or cytotoxic T lymphocytes which recognise and kill endothelial cells overexpressing these antigens, then the approach is tested for efficacy and potential toxicity in a mouse model. T cell epitopes which bind to both human HLA-A24 and Balb/c H-2K^d may be used as both these sets of alleles have similar requirements for T cell epitope binding (Brusic, et al., 1994 *supra*). These epitopes may also represent regions of the receptors which show homology between the mouse and human proteins. If this is not possible then peptides binding to mouse MHC representing protein sequences from the respective mice receptors are identified in accordance with the disclosures herein.

15

Mice are immunised with the constructs outlined above. CTL and blastogenesis responses are measured. Mice carrying tumours are immunised to test for therapeutic effects and the potential toxic effect on wound healing assessed. Candidate vaccines are tested in phase I clinical trials.

CLAIMS

1. A peptide which comprises less than the full-length polypeptide sequence of native Tek, and which consists essentially of one or more amino acid sequences which represent one or more epitopes of the Tek protein, which peptide can bind to an MHC molecule and stimulate an immune response.
5
- 10 2. A peptide according to claim 1 which consists essentially of an amino acid sequence representing a single epitope of the Tek protein.
- 15 3. A peptide according to claim 1 which consists essentially of an amino acid sequence representing two or more epitopes of the Tek protein.
- 20 4. A peptide according to claim 3 wherein the amino acid sequence is such that the said two or more epitopes are contiguous or substantially contiguous.
- 25 5. A peptide according to claim 3 or claim 4 wherein the amino acid sequence is substantially devoid of the amino acid sequence that occurs between neighbouring epitopes in the native Tek protein.
- 30 6. A peptide according to any one of the preceding claims wherein said one or more amino acid sequences represent an amino acid sequence which appears within an amino acid sequence region selected from TEK1 (amino acids 55 to 90), TEK2 (amino acids 163 to 176), TEK3 (amino acids 345 to 362), TEK4 (amino acids 427 to 442) and/or TEK5 (amino acids 530 to 542) of the Tek polypeptide as shown in Fig. 1 or
35 which appears within equivalent amino acid sequence

regions in a variant form of said Tek polypeptide with substantially the same functional attributes.

7. A peptide according to any one of claims 1 to 6 which comprises one or more of the epitope sequences Z1, Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9, Z11, Z12 and Z32 as set forth in Tables 1 and 4, and/or one or more of a variant form of said "Z" epitope sequences with substantially the same functional attributes.
- 10 8. A peptide according to any one of the preceding claims which binds HLA-A2 with a stabilisation ratio of 1.3 or greater.
- 15 9. A peptide according to claim 8 which can stimulate T cell proliferation.
10. A peptide according to claim 8 or claim 9 which binds HLA-A2 with a stabilisation ratio of 1.5 or
20 greater.
11. A peptide according to any one of claims 8 to 10 which binds HLA-A2 with a stabilisation ratio of 2.3.
- 25 12. A peptide according to any one of the preceding claims which is in an isolated and/or purified form, free or substantially free of material with which it is naturally associated.
- 30 13. A polypeptide which comprises a peptide according to any one of claims 1 to 12 and one or more amino acid sequences not characteristic of Tek protein.
- 35 14. A polypeptide according to claim 13 which is a

fusion protein.

15. The use of a peptide according to any one of claims 1 to 12 or of a polypeptide according to claim 13 or 5 claim 14 in the formulation of a composition for use in prophylactic and/or therapeutic treatment.
16. The use of a peptide according to any one of claims 1 to 12 or of a polypeptide of claim 13 or claim 14 10 in the production of epitope-specific antibodies capable of reacting with epitopes of wild-type Tek polypeptide.
17. The use according to claim 16 wherein said 15 antibodies are monoclonal antibodies.
18. An antibody capable of specifically binding to a peptide of any one of claims 1 to 12 or a polypeptide according to claim 13 or claim 14. 20
19. An antibody according to claim 18 which is capable of reacting with wild-type Tek polypeptide.
20. An antibody according to claims 18 or 19 which is a 25 monoclonal antibody.
21. A fragment, derivative, functional equivalent or homologue of an antibody according to claim 18, claim 19 or claim 20. 30
22. A fragment according to claim 21 which comprises an Fab fragment consisting of VL, VH, C1 and CH1 domains; an Fd fragment consisting of VH and CH1 domains; an Fv fragment consisting of VL and VH domains of a single arm of an antibody; a dAb 35

fragment which consists of a VH domain; an isolated CDR region or F(ab')₂ fragment; or a single chain Fv fragment.

- 5 23. A cell culture capable of producing an antibody, fragment, derivative, functional equivalent or homologue according to any one of claims 18 to 22.
- 10 24. A cell culture according to claim 23 wherein the cells are hybridomas.
- 15 25. A nucleic acid sequence which codes for an antibody, fragment, derivative, functional equivalent or homologue according to any one of claims 18 to 22.
- 20 26. A recombinant DNA construct or virus vector which comprises a nucleic acid sequence encoding a peptide according to any one of claims 1 to 12 or a polypeptide according to claim 13 or claim 14.
- 25 27. A recombinant DNA construct or virus vector according to claim 26 which has one or more regulatory sequences for controlling the expression of said peptide.
- 30 28. A recombinant DNA construct according to claim 26 or claim 27 which is a plasmid.
- 35 29. A host cell containing and capable of expressing a nucleic acid encoding a peptide according to any one of claims 1 to 12 or a polypeptide according to claim 13 or claim 14.
- 35 30. A method of producing an antibody, fragment, derivative, functional equivalent or homologue

according to any one of claims 18 to 22, including the step of growing a cell capable of producing the antibody under conditions in which the antibody is produced.

5

31. A pharmaceutical composition for use as a vaccine to target endothelial cells lining the blood vessels of a tumour, said composition comprising a peptide according to any one of claims 1 to 12 or a polypeptide according to claim 13 or claim 14 or a recombinant DNA construct or virus vector according to any one of claims 26 to 28.
- 10
32. A method of preparing a pharmaceutical composition according to claim 31, said method optionally including the step of combining said peptide, polypeptide, recombinant DNA construct or virus vector with a pharmaceutically acceptable excipient, carrier, buffer or stabiliser.
- 15
- 20
33. A nucleic acid encoding a peptide of any one of claims 1 to 12 or a polypeptide according to claim 13 or claim 14.
- 25
34. A method of obtaining a nucleic acid encoding a peptide of any one of claims 1 to 12, the method including hybridising a probe having a sequence encoding a peptide of Tek regions TEK1 to 5 or a peptide as identified in Tables 1 and 4, or a complementary sequence thereof, to target nucleic acid.
- 30
- 35
35. A method according to claim 34 including the step of amplifying said target nucleic acid by PCR methods.

36. A method of producing a peptide according to any one of claims 1 to 12 or a polypeptide according to claim 13 or claim 14 which includes the step of
5 expressing a nucleic acid of claim 33 in an expression system.
37. A vector comprising a nucleic acid of claim 33.
- 10 38. A vector according to claim 37 which is a plasmid.
39. A vector according to claim 37 which is a virus.
- 15 40. A host cell containing a vector according to claim 37, claim 38 or claim 39.
41. A method of therapeutic or prophylactic treatment of a patient, comprising administering an effective amount of a pharmaceutical composition of claim 31.
20
42. A method according to claim 41 comprising inoculating said patient at least three times with said pharmaceutical composition, the second inoculation being administered more than two weeks
25 after the first inoculation.
43. A method of therapeutic or prophylactic treatment of a patient, which comprises introducing a sequence encoding a peptide according to any one of claims 1 to 12, or a polypeptide according to claim 13 or
30 claim 14, into target host cells of the patient.

Figure 1

- A - AMPHI mid points of blocks.
- R - Residues matching the Rothbard/Taylor motif.
- D - Residues matching the IAd motif.
- d - Residues matching the IEd motif.

5 10 15 20 25 30 35 40 45 50 55 60, 65 70 75
MDSLASLVLCGVSLLLSGTVEGAMDLILINSLPLVSDAETSLTCIASGWRPHEPITIGRDFEALMNQHQDPLEVT
.....AAA.....AAAAAA..AAAAAAAAAAAAAA
.....RRRRRRRRR.....RRRRR.....RRR
....DDDDDD.DDDDDDD.....DDDDDDDDDD.....DD

80 85 90 95 100 105 110 115 120 125 130 135 140 145 150
QDV TREWAKKVVWKREKASKINGAYFCEGRVRGEAIRIRTMKMRQQASFLPATLTMTVDKGDNVNISFKKVLIKE
AAAAAAA.....AAA.....
RRRRRRRRRRRRR.....RRRR.RRRR.....RRRRR.
DDDD.....DDDDDDDD.....DDDDDD.....ddddd.

155 160 165 170 175 180 185 190 195 200 205 210 215 220 225
EDAVIYKNGSFIHSVPRHEVPDILEVHLPHAQQPQDAGVYSARYIGGNLFTSAFTRLIVRRCEAQKWGPECNLCT
.....AAAAAAA.....AAAAAA.....AAAAA.....AAAA
.....RRRR.....RRRR.RRRR.....RRRRR.
.....DDDDDD.....DDDDDD.....

230 235 240 245 250 255 260 265 270 275 280 285 290 295 300
ACMNNGVCHEDTGECICPPGMGRTEKACELHTFGRTCKERCSGQEGCKSYVFCLPDYPGCSCATGWKGLQCNE
AAAA.....AAAAAAA.....AAA.....AAA.....AAA.....AAA
.....RRRR.....RRRR.....

305 310 315 320 325 330 335 340 345 350 355 360 365 370 375
ACHPGFYGPDKLRCSCNNGEMCDRFQGCLCSPGWQGLQCEREGIPRMTPKIVDLPDHIEVNSGKFNPICKASGW
.AAA.....AAAAAAA.....AAAAAAA.....AAAAAA.....AAAAA...
....RRRR.....RRRRR.....
....DDDDDD.....

380 385 390 395 400 405 410 415 420 425 430 435 440 445 450
PLPTNEEMTLVKPDGTVLHPDFNHTDHFSVAIFTIHRILPPDSGVWVCVNTVAGMVEKPFNISVKVLPKPLNA
.....AAAAAAA.....AAA.....AAAA.....AAAAAAA.....AAAAAAA.....AAAAAAA
....RRRRR.....RRRR.....RRRR.....RRRRR.....

455 460 465 470 475 480 485 490 495 500 505 510 515 520 525
PNVIDTGHNFAVINISSEPYFGDGPIKSKKLLYKPVNHYEAWQHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEG
AAAAAAA.....AAAAAAA.....AAAAAAA.AA.....
....RRRR.....RRRR.....RRRR.....

Figure 1 (cont.)

530 535 540 545 550 555 560 565 570 575 580 585 590 595 600
 GEGHPGPVRRFTTASIGLPPPRGLNLLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSV
AAAAAAA.....AAAAAAA.....AAAAAAA.....AAAAAAA
RRRR.....RRRRR.....RRRRR.....RRRRR
DDDD

 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675
 LLNNLHPREQYVVRARVNTKAQGEWSEDLTAWTLSILPPQOPENIKISNITHSSAVISWTILDGYSISSITIRYK
 AAA.....AAAAA..AAAAA.....AA..AAA.....AAAAAAA.....
DDDDDDDDDD.....DDDDDD

 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750
 VQGKNEDQHVDVKIKNATIIQYQLKGLEPETAYQVDIFAENNIGSSNPASFHELVTLPESQAPADLGGGKMLLIA
AAAAA.....RRRRR.RRRRR.....RRRR.....RRRR
DDDDDD

 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825
 ILGSAGMTCLTVLLAFLIILQLKRANVQRRMAQAFQNVREEPAVQFNSGTALNRKVKNPDPTIYPVLDWNDIK
AAA.....AAAAAAA.....AAAAA.....AAAA.....A
RRRR.....RRRR.....RRRR.....RRRR
DDDDDD
dddd.....dddd

 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900
 FQDVIGEGNFGQVLKARIKKDGLRMDAAIKRMKEYASKDDHRDFAGELEVCKLGHHPNIINLLGACEHRGYLYL
 AA.....AAAAA.....AAAAAAA.....AAAA.AAAA.....AAAAAAA.....AAAAA
 ..RRRR.....RRRR...RRRR.....RRRR.....RRRR
DDDDDD
dddd.....dddd

 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975
 AIEYAPHGNLLDFLRKSRVLETDPAFAIANSTASTLSSQQLLHFADVARMDYLSQKQFIHRDLAARNILVGEN
AAAAAAA.....AAA.....AAA.....AAAAAAA.....
 ..RRRRR....RRRR..RRRR.....RRRRRRR..RRRR.....RRRR
DDDDDDDDDD
dddd

 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050
 YVAKIADFGLSRGQEYVKKTMGRLPVRWMAIESLNYSVYTTNSDVWSYGVLLWEIVSLGGTPYCGMTCAELYEK
 AAAA.....AAAAA.....AAA.....AAA.....AAA.....AAAA.....AAAAA
 ...RRRR.....RRRRRRRR.....RRRR.....RRRR.....RRRR

 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125
 LPQGYRLEKPLNCDEDEVYDLMRQCWRKPYERPSFAQILVSLNRMLEERKTYVNTTLYEKFTYAGIDCSAEEAA
 AAAA.....AAAAA.....AAAAA.....AAAAA.....AAAAA.....
RRRRRRR.....RRRR.....RRRR.....RRRR
DDDDDD

Potential T cell epitopes:

TEK 1 aa 55-90
 TEK 2 aa 163-176
 TEK 3 aa 345-362

TEK 4 aa 427-442
 TEK 5 aa 530-542

Figure 2

TEK = TIE2

Approx position 1

50

Figure 2 (cont.)

TEK	LSDILPPQOPENIKISNITHSSAVISWTILDGYSISSITIRYKVQGKNEDQ
TIE1	LPPSGPPAPRHLHAQALSDSEIQLTWKHPEA--LPGPISKYVVEVQVAGG *. *** ** .. * * * ..
TEK	HVD---VKIKNATIIQYQLKGLEPETAY-----QVDIFAENNIGSSNPA
TIE1	AGDPLWIDVDRPEETSTIIRGLNASTRYLFRMRASIQGLGDWSNTVEEST ****.. * *
TEK	FSHELVT---LPESQAPADLGGGKMLLIAILGSAGMTCLTVLLAFLIILQ
TIE1	LGNGLQAEGPVQESRAAEE-GLDQQLILAVVGSVSATCLTILAALLTLVC ... * .. . **.*. . * .. *..**..* . * * * . * .. *
TEK	LKRANVQRRMAQAFQNVR-EEPAVQFNSGTLALNRKVKNNPDTIYPVLD
TIE1	IRRSLHRRRTFTYQSGSGEETILQFSSGTLTLTRRPKLQPEPLSYVLE ..*.. . **. . . * .. ** .. * . * . * .. * .. *
TEK	WNDIKFQDVIGEGNFGQVLKARIKKDGLRMDAAIKRMKEYASKDDHRDFA
TIE1	WEDITFEDLIGEGNFGQVIRAMIKKDGLKMNAAIKMLKEYASENDHRDFA * . ** * . *.*****. . * . *****. * . * . * .. * . *****
TEK	GELEVLCALKHHPNIINLLGACEHRGYLYIAIEYAPHGNLLDFLRKSRVL
TIE1	GELEVLCALKHHPNIINLLGACKNRGYLYIAIEYAPYGNLLDFLRKSRVL *****.*****.*****.*****.*****.*****.*****.*****.*****
TEK	ETDPAFAIANSTASTLSSQQLLHFADVARMDYLSQKQFIHRDLAARNI
TIE1	ETDPAFAREHGTASTLSSRQLRFASDAANGMQYLSEKQFIHRDLAARNV *****.*****.*****.*****.*****.*****.*****.*****.*****.
TEK	LVGENYVAKIADFGLSRGQEYVVKTMGR LPVRWMAIESLNYSVYTTNSD
TIE1	LVGENLASKIADFGLSRGEEYVVKTMGR LPVRWMAIESLNYSVYTTKSD *****.*****.*****.*****.*****.*****.*****.*****.*****.**
TEK	VWSYGVLLWEIVSLGGTPYCGMTCAELYEKL P QGYRLEKPLNCDEVYDL
TIE1	VWSFGVLLWEIVSLGGTPYCGMTCAELYEKL P QGYRMEQPRNCDEVYEL ***.*****.*****.*****.*****.*****.*****.*****.*****.***
TEK	MRQCWREKPYERPSFAQILVSLNRMLEERKTYVNNTLYEKFTYAGIDCSA
TIE1	MRQCWRDRPYERPPFAQIALQLGRMLEARKAYVNMSLFENFTYAGIDATA *****.*****.*****.*****.*****.*****.*****.*****.*****.*****
TEK	EEAA
TIE1	EEA- ***

Potential epitopes as located on Fig. 1 (same numbering system used)




Figure 3




Figure 4




Figure 5

INTERNATIONAL SEARCH REPORT

Interr nal Application No

PCT/GB 99/00583

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C12N15/12	C07K14/71	A61K38/17	A61K39/00	G01N33/50
	G01N33/68	C12Q1/68	C07K16/28		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 21866 A (LUDWIG INSTITUTE FOR CANCER RES (US); RUNTING AS; WILKS AF; STACKER SA) 17 August 1995 see page 21, line 18 - page 22, line 21 --- X WO 94 00469 A (IMMUNEX CORPORATION (US); ZIEGLER S.F.) 6 January 1994 see page 9, line 19-24 see page 26, line 4-37; example 4 Seq.ID:2 see page 34 - page 37 ---	1-5, 12-30, 33-40
		1-5, 12-30, 33-40

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

25 June 1999

Date of mailing of the international search report

02/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/00583

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 681 714 A (MOUNT SINAI HOSPITAL CORP (CA); BREITMAN; ROSSANT; DUMONT; YAMAGUCHI) 28 October 1997 see column 18, line 3-53 see column 23, line 44-67 see column 34, line 24-38 ---	1-5, 12-30, 33-40
X	WO 95 13387 A (MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN EV (DE) RISAU) 18 May 1995 see page 27, line 32 - page 29, line 33 ---	1-5, 12-30, 33-40
A	D'AMARO J. ET AL.: "A computer program for predicting possible cytotoxic T lymphocytes epitopes based on HLA class I peptide-binding motifs" HUMAN IMMUNOLOGY, vol. 43, no. 1, 1 May 1995, pages 13-18, XP002015451 see abstract ---	
A	DAVENPORT M.P. ET AL.: "An empirical method for the prediction of T-cell epitopes" IMMUNOGENETICS, vol. 42, no. 5, 1 January 1995, pages 392-397, XP002015224 see abstract ---	
A	WO 97 41440 A (UNIV LEIDEN; SEED CAPITAL INVESTMENTS (SCI) BV (NL) VAN DER BURG ET AL) 6 November 1997 see abstract ---	
A	RESSING M.E. ET AL.: "Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity" IMMUNOTECHNOLOGY, vol. 2, no. 4, 1 November 1996, page 241-251 XP004063120 see abstract -----	

INTERNATIONAL SEARCH REPORT

I. International application No.

PCT/GB 99/00583

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 41-43 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/00583

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9521866 A	17-08-1995	AU 1874595 A CA 2182681 A EP 0812332 A JP 10503081 T			29-08-1995 17-08-1995 17-12-1997 24-03-1998
WO 9400469 A	06-01-1994	AU 4651893 A US 5447860 A			24-01-1994 05-09-1995
US 5681714 A	28-10-1997	CA 2085291 A			31-01-1994
WO 9513387 A	18-05-1995	AU 8143094 A			29-05-1995
WO 9741440 A	06-11-1997	AU 2410697 A EP 0900380 A			19-11-1997 10-03-1999